Nom du produit:5-Fluorooxindole
IUPAC Name:5-fluoro-2,3-dihydro-1H-indol-2-one
- CAS:56341-41-4
- Formule moléculaire:C8H6FNO
- Pureté:95%+
- Numéro de catalogue:CM148054
- Poids moléculaire:151.14
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:56341-41-4
- Formule moléculaire:C8H6FNO
- Point de fusion:-
- Code SMILES:C1=C2C(=CC=C1F)NC(=O)C2
- Densité:
- Numéro de catalogue:CM148054
- Poids moléculaire:151.14
- Point d'ébullition:307.2°C at 760 mmHg
- N° Mdl:MFCD02179598
- Stockage:Keep in a tight container and store at ambient temperature
Category Infos
- Indolinones
- Indolinone derivatives have in common the presence of a hydrogen bond between the C-2 carbonyl and a hydrogen donor in a side chain, generally a pyrrole ring. Indolinone displays very promising antitumor properties by inhibiting various kinase families.
Column Infos
- Vorolanib
- EyePoint Pharmaceuticals announced on December 4th announced positive topline results of its Phase 2 DAVIO 2 trial of EYP-1901, an investigational sustained delivery maintenance treatment for wet age-related macular degeneration (wet AMD) combining vorolanib, a selective tyrosine kinase inhibitor with bioerodible Durasert E™. Vorolanib brings a new mechanistic approach to the treatment of VEGF-mediated retinal diseases as a pan-VEGF receptor blocker, blocking all VEGF isoforms. Vorolanib features reduced off-target binding and at clinically relevant doses does not inhibit Tie-2, a critical pathway associated with vascular stability, which may result in an improved efficacy. Further, in an in-vivo model of retinal detachment, vorolanib demonstrated neuroprotection, and potential antifibrotic benefits.